Innovation New Jersey
  • Home
  • Our Coalition
    • Contact Us
  • News
  • Resources
    • State Supports
    • Federal Supports
    • Higher Ed Supports
  • Join Us

Innovation News

Everything Innovation. Everything New Jersey.
Follow us and stay connected.

Rutgers Interview: New Treatment Delivery Methods of Medication for Opioid Addiction Show Promise

3/3/2017

0 Comments

 
New Brunswick, NJ — Rutgers Today’s Patti Verbanas spoke to Petros Levounis, professor and chair of the Department of Psychiatry at Rutgers New Jersey Medical School and a member of the board of directors at the American Society of Addiction Medicine, about recent advancements in opioid treatment delivery methods and the most effective combination of therapies for recovery.
 
Every day, 91 Americans die from an opioid overdose, according to the Centers for Disease Control and Prevention.  Nationwide, physicians and legislators are ramping up efforts to stem the escalating heroin and prescription opioid addiction crisis.
 
Gov. Chris Christie recently signed a bill requiring insurance companies to cover up to six months of inpatient and outpatient treatment for drug addiction and limit an opioid prescription to a five-day supply to strengthen efforts to prevent drugs from reaching children and other vulnerable populations.
 
Treatment methods, however, vary in efficacy — complicating the efforts of people with opioid use disorder to sustain recovery. 
​Where do we stand on new delivery methods of opioid addiction medication for improving recovery rates?
 
Levounis: Traditionally, there were two main pharmacological approaches. We would prescribe agonist medications, like methadone, which activates the opioid system in a way similar to heroin or prescription opioids and allows the person to feel normal while reducing withdrawal symptoms.
 
The other approach is an antagonist medication like naltrexone, which blocks the opioid systems and helps people to manage their addiction by stopping them from feeling high if they take a problem drug.
 
Over the past several years, we have developed a third strategy, a partial agonist — buprenorphine — which combines the two approaches to help people reduce their dependence and curb withdrawal symptoms.
 
The downside is that patients must take the medication — typically a tablet or a film placed under the tongue — every day. If they forget, they are at risk for withdrawal and relapse.
 
In an exciting development, the FDA recently approved buprenorphine implants, which provide long-term maintenance. This is the first time an implant has been approved for the treatment of opioid addiction in the U.S.
 
In this outpatient procedure, a small incision is made underneath the inner upper arm for four one-inch implants, providing a constant low-level dose of buprenorphine. After six months, the doctor assesses if another six-month dose is necessary.
 
Eligible patients are those who are already stable on low-to-moderate doses of other forms of buprenorphine. As doctors undergo training in the procedure, it is becoming more available. I expect this treatment method will be accessible to our patients by this summer.
 
What other improvements of delivery are on the horizon?
 
Levounis: Buprenorphine injections, which will be effective for two weeks to a month, are in clinical trial, but have not yet been approved by the FDA.
 
What medical challenges do these advances in delivery resolve?
 
Levounis: Patient adherence to a pharmacological regimen is crucial to success — but it is the most challenging for practitioners to uphold. When patients are ill, they readily accept medications.
 
However, when they start to feel healthy, their inclination is to stop taking the medication. The implants allow the medication to do its job without people thinking about it, which substantially reduces the risk of relapse.
 
What is the most effective course of treatment for opioid use disorder?
 
Levounis: Scientific evidence shows that a maintenance approach with medications used in combination with behavioral treatment and recovery support are more effective than detoxification programs aimed at abstinence.
 
In fact, a vast majority of people who go through a detoxification program without continuing on with pharmacological treatment end up relapsing.
 
Going through detox only can be dangerous. What few people understand is that during detoxification the patient’s tolerance level to the opioids is reset.
 
For example, heroin addicts know the exact dose they need to take each day to keep themselves from withdrawing or overdosing. If they go through detox, do not continue on with treatment and relapse, they likely will return to taking the same amount of heroin as before. However, because they have lost tolerance, that dose is now lethal.
0 Comments



Leave a Reply.

    Do not miss a single innovative moment and sign up for our newsletter!
    Weekly updates


    Categories

    All
    3D Printing
    Academia
    Acquisitions
    Aerospace
    Agriculture
    AIDS
    Algae
    Alumni
    Animals
    Architecture
    Astrophysics
    Autism
    Awards
    Big Data
    Bioethics
    Biofuel
    Biomedical
    BioNJ
    Bioterrorism
    Bit Coins
    Brain Health
    Business
    Camden
    Cancer
    CCollege
    Cellular
    Centenary
    Chemistry
    ChooseNJ
    Climate Change
    Clinical Trials
    Cloud Tech
    Collaboration
    Computing
    Congress
    Coriell
    Council On Innovation
    Crowdfunding
    Cybersecurity
    DARPA
    Defense
    Degree
    Dementia
    Dental Health
    DOC
    DOD
    DOE
    Drew
    Drones
    Drug Creation
    Einstein's Alley
    Electricity
    Energy
    Engineering
    Entrepreneurship
    Environmental
    FAA
    Fairleigh Dickinson
    FDA
    Federal Budget
    Federal Government
    Federal Labs
    Federal Program
    Finance
    Food Science
    Fort Monmouth
    Fuel Cells
    Funding
    Genome
    Geography
    Geology
    Global Competition
    Google
    Governor Christie
    Grant
    Hackensack
    HackensackUMC
    Healthcare
    Health Care
    HHS
    HINJ
    Hospitals
    Immigration
    Incubator
    Infrastructure
    International
    Internet
    Investor
    IoT
    IP
    IT
    Jobs
    Johnson & Johnson
    K-12
    Kean
    Kessler
    Legislation
    Logistics
    Manufacturing
    Medical Devices
    Med School
    Mental Health
    Mentor
    Microorganisms
    Molecular Biology
    Montclair
    NAS
    Neuroscience
    Newark
    New Jersey
    NIFA
    NIH
    NIST
    NJBDA
    NJBIA
    NJ Chemistry Council
    NJCU
    NJDOLWD
    NJEDA
    NJEDge
    NJHF
    NJII
    NJIT
    NJMEP
    NJPAC
    NJPRO
    NJTC
    Nonprofit
    NSF
    OpEd
    Open Data
    OSHE
    OSTP
    Parasite
    Patents
    Paterson
    Patients
    Perth Amboy
    Pharma
    POTUS
    PPPL
    Princeton
    Prosthetics
    Ranking
    Rare Disease
    R&D Council
    Report
    Resiliency
    Rider
    Robotics
    Rowan
    Rutgers
    SBA
    Seton Hall
    Siemens
    Smart Car
    Smart Cities
    Software
    Solar
    Space
    SSTI
    Startup
    State Government
    STEM
    Stevens
    Stockton
    Subatomic
    Supports
    Sustainability
    Taxes
    TCNJ
    Teachers
    Telecom
    Therapy
    Thermodynamics
    Transportation
    Undergraduate
    USEDA
    Verizon
    Video Game
    Virtual Reality
    Water
    WHO
    William Paterson
    Women In STEM
    Workforce Development

Home   Coalition   News   Resources   Events   Join Us
Picture
Innovation New Jersey Coalition
10 West Lafayette Street
Trenton, NJ 08608-2002
609-858-9507